Spyre Therapeutics, Inc.

NASDAQ:SYRE

Biotechnology

Healthcare
$101.46 +1.38%

+$1.21 today

Market cap
$9.64B
Beta
3.06
P/E (TTM)
-171.1
EPS (TTM)
-$0.52
52W Low $14.00High $91.04

Volume 1.37M

Average 1.17M

SYRE EBITDA Margin

EBITDA as a percentage of revenue.

Spyre Therapeutics, Inc.NASDAQ: SYRE

EBITDA Margin · Q3 FY2026 · quarter ended Sep 2026

EBITDA Margin not reported for Q3 FY2026

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
—— QoQ
Last fiscal yearDec 2025
—— YoY
LTMSep 2026
-309.5%— YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2023
-14426.6%
Year-over-year change
-10906.4pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How SYRE compares with its peers on the latest reported figures

  • SYRE's LTM Sep 2026 EBITDA Margin of -309.5% is the 3rd highest of the 6 companies compared; the peer median is -843.9%.
SYRE Competitors Peer median
EBITDA Margin for SYRE and competitors
Company Period LTM level YoY 3-year change
ANABAnaptysBio, Inc.LTM Mar 202625.2% +93.4 pp+1052.7 pp
ARDXArdelyx, Inc.LTM Mar 2026-6.0% +1.8 pp+109.8 pp
SYRESpyre Therapeutics, Inc.LTM Sep 2026-309.5% ——
ACRSAclaris Therapeutics, Inc.LTM Mar 2026-843.9% -542.0 pp-540.2 pp
UPBUpstream Bio, Inc.LTM Mar 2026-4713.1% -1269.6 pp-3050.7 pp
IFRXInflaRx N.V.LTM Mar 2026-144435.8% -111246.8 pp—
ABVXAbivax S.A.FY2025— ——
ODTXOdyssey Therapeutics, Inc.—— ——
AGMBAgomAb Therapeutics N.V. American Depositary SharesFY2024— ——
IMUXImmunic, Inc.FY2025— ——
Peer median (excluding SYRE) -843.9%-542.0 pp-215.2 pp

Competitors are the stored peer set for SYRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue18.74M2.33M886K00
Cost of Revenue0000171.65M
Gross Profit18.74M2.33M886K0(171.65M)
Gross Margin100.0%100.0%100.0%——
Research & Development57.07M58.58M89.5M162.79M171.65M
Selling, General & Admin27.32M28.53M39.95M45.78M47.91M
Operating Expenses84.39M87.11M243.19M208.57M37.91M
Depreciation & Amortization1.58M1.96M744K010M
EBITDA(64.08M)(81.99M)(127.82M)(207.97M)(209.56M)
EBITDA Margin-342.0%-3520.3%-14426.6%——
Operating Income(65.65M)(84.78M)(242.3M)(208.57M)(209.56M)
Operating Margin-350.3%-3640.2%-27348.0%——
Interest Income111K837K6.15M21.31M24.89M
Interest Expense00000
Other Income / Expenses(11K)830K(96.51M)599K54.34M
Income Before Tax(65.66M)(83.95M)(338.82M)(207.97M)(155.22M)
Pre-Tax Margin-350.4%-3604.6%-38241.1%——
Income Tax Expense141K(136K)(26K)51K(15K)
Net Income(65.8M)(83.82M)(338.79M)(208.02M)(155.2M)
Net Margin-351.1%-3598.8%-38238.1%——
EPS (Basic)(25.02)(24.86)(46.15)(3.18)(1.98)
EPS (Diluted)(25.02)(24.86)(46.15)(3.18)(1.98)
Weighted Avg Shares2.63M3.37M6.9M47.03M64.06M
Weighted Avg Shares (Diluted)2.63M3.37M6.9M47.03M64.06M

Spyre Therapeutics, Inc.

NASDAQ:SYRE

Intrinsic Alpha fair value

Locked

Current Price

$101.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.